Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Talha Badar

Showing results (71-80 of 113) with videos related to

Pageof 12
Sort By:
Haematologica|May 21, 2026
Insights into clonal and complete blood count changes at disease evolution among patients with clonal cytopenia of undetermined significanceYazan Jabban, Rong He, Kurt Bessonen, et al.
Haematologica|July 9, 2026
Characteristics of clonal cytopenia of undetermined significance in the presence of <i>ZRSR2</i> mutationsMahmoud Yacout, Bahga Katamesh, Yazan Jabban, et al.
Leukemia & Lymphoma|April 9, 2026
Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Razan Mohty, Ravi Narra, Alice S Mims, et al.
Blood Neoplasia|April 30, 2026
Outcomes of hemophagocytic lymphohistiocytosis in acute myeloid leukemia: the 3-site Mayo Clinic experienceJabra Zarka, Clifford M Csizmar, Syeda Mina, et al.
Haematologica|May 30, 2024
Prognostic impact of 'multi-hit' <i>versus</i> 'single-hit' <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic DiseasesTalha Badar, Ahmad Nanaa, Ehab Atallah, et al.
Haematologica|January 8, 2026
Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in <i>TP53</i>-mutated myelodysplastic syndromesMahmood Aldapt, Yu-Hung Wang, Kashish J Shah, et al.
Haematologica|February 1, 2024
Genetic landscape and clinical outcomes of patients with <i>BCOR</i> mutated myeloid neoplasmsAnmol Baranwal, Mark Gurney, Rami Basmaci, et al.
Cancer|December 1, 2020
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemiaTalha Badar, Aniko Szabo, Shira Dinner, et al.
Blood Cancer Journal|August 11, 2023
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive eventsMaymona G Abdelmagid, Aref Al-Kali, Mark R Litzow, et al.
The Lancet. Haematology|February 10, 2025
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trialJorge E Cortes, Dong-Wook Kim, Tapan Saikia, et al.
Pageof 12

Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
Haematologica|May 21, 2026
Insights into clonal and complete blood count changes at disease evolution among patients with clonal cytopenia of undetermined significanceYazan Jabban, Rong He, Kurt Bessonen, et al.
Haematologica|July 9, 2026
Characteristics of clonal cytopenia of undetermined significance in the presence of <i>ZRSR2</i> mutationsMahmoud Yacout, Bahga Katamesh, Yazan Jabban, et al.
Leukemia & Lymphoma|April 9, 2026
Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Razan Mohty, Ravi Narra, Alice S Mims, et al.
Blood Neoplasia|April 30, 2026
Outcomes of hemophagocytic lymphohistiocytosis in acute myeloid leukemia: the 3-site Mayo Clinic experienceJabra Zarka, Clifford M Csizmar, Syeda Mina, et al.
Haematologica|May 30, 2024
Prognostic impact of 'multi-hit' <i>versus</i> 'single-hit' <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic DiseasesTalha Badar, Ahmad Nanaa, Ehab Atallah, et al.
Haematologica|January 8, 2026
Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in <i>TP53</i>-mutated myelodysplastic syndromesMahmood Aldapt, Yu-Hung Wang, Kashish J Shah, et al.
Haematologica|February 1, 2024
Genetic landscape and clinical outcomes of patients with <i>BCOR</i> mutated myeloid neoplasmsAnmol Baranwal, Mark Gurney, Rami Basmaci, et al.
Cancer|December 1, 2020
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemiaTalha Badar, Aniko Szabo, Shira Dinner, et al.
Blood Cancer Journal|August 11, 2023
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive eventsMaymona G Abdelmagid, Aref Al-Kali, Mark R Litzow, et al.
The Lancet. Haematology|February 10, 2025
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trialJorge E Cortes, Dong-Wook Kim, Tapan Saikia, et al.
Pageof 12